Intercept Pharmaceuticals Inc (OQ:ICPT)

Mar 26, 2020 08:00 am ET
Intercept Pharmaceuticals Provides Regulatory and Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the rescheduling of its advisory...
Feb 28, 2020 08:00 am ET
Intercept to Present at the Cowen 40th Annual Health Care Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President...
Feb 25, 2020 07:00 am ET
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth...
Feb 18, 2020 08:00 am ET
Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2019...
Jan 29, 2020 08:00 am ET
Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient...
Jan 08, 2020 08:00 am ET
Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President...
Dec 13, 2019 08:00 am ET
Intercept Provides Regulatory Update
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has submitted its Marketing...
Dec 10, 2019 08:00 am ET
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Day...
Dec 05, 2019 07:00 pm ET
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the...
Dec 02, 2019 08:00 am ET
Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna,...
Nov 25, 2019 08:00 am ET
FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug...
Nov 08, 2019 07:00 am ET
New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from the...
Nov 05, 2019 07:00 am ET
Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Oct 29, 2019 08:00 am ET
Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2019 financial results...
Oct 28, 2019 08:00 am ET
Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts on obeticholic...
Sep 27, 2019 04:05 pm ET
Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has submitted a New Drug...
Sep 25, 2019 08:00 am ET
Intercept to Present at Upcoming Investor Conference in October
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
Sep 11, 2019 08:00 am ET
Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the launch of NASHTRUTH.com, a new...
Sep 09, 2019 08:00 am ET
Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Lisa DeFrancesco as...
Aug 23, 2019 08:00 am ET
Intercept to Present at Upcoming Investor Conferences in September
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating...
Aug 07, 2019 07:05 am ET
Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Jul 31, 2019 08:00 am ET
Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2019 financial results...
May 30, 2019 07:00 am ET
Intercept to Present at Upcoming Investor Conferences in June
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its management will be presenting...
May 10, 2019 04:05 pm ET
Intercept to Present at Upcoming Investor Conferences in May
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
May 10, 2019 08:30 am ET
Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its underwritten...
May 08, 2019 04:05 pm ET
Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten...
May 08, 2019 07:00 am ET
Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
May 01, 2019 07:00 am ET
Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results...
Apr 11, 2019 02:00 am ET
Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from its...
Apr 04, 2019 07:00 am ET
Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple OCA abstracts will be...
Mar 05, 2019 05:00 pm ET
Intercept to Present at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
Mar 05, 2019 08:30 am ET
New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influe
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American Tower Corporation (REIT) (NYSE:AMT), Lowe's Companies, Inc....
Feb 28, 2019 07:15 am ET
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth...
Feb 20, 2019 04:30 pm ET
Intercept to Announce Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2018...
Feb 19, 2019 08:31 am ET
Thinking about buying stock in Advanced Micro Devices, Intercept Pharmaceuticals, Newell Brands Inc., Walmart Stores Inc. or Zoetis?
NEW YORK, Feb. 19, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, ICPT, NWL, WMT, and ZTS....
Feb 19, 2019 07:00 am ET
Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced positive results from its pivotal Phase...
Jan 07, 2019 07:00 am ET
Intercept Announces NASH and PBC Program Updates
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two updates to its NASH development...
Jan 02, 2019 04:05 pm ET
Intercept to Present at Upcoming Investor Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
Dec 03, 2018 07:50 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Caesars Entertainment, Intercept Pharmaceuticals, Exxon Mobil, Teligent, Amerco, and Mettler-Toledo International — New Research Emp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation (NASDAQ:CZR), Intercept Pharmaceuticals,...
Nov 05, 2018 07:00 am ET
Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid (OCA)...
Oct 31, 2018 07:05 am ET
Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Oct 24, 2018 04:05 pm ET
Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2018 financial results...
Oct 24, 2018 07:50 am ET
Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and ViewRay — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vitamin Shoppe, Inc (NYSE:VSI), Intercept Pharmaceuticals, Inc....
Sep 26, 2018 07:05 am ET
Intercept to Present at Upcoming Investor Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
Aug 29, 2018 07:05 am ET
Intercept to Present at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
Aug 02, 2018 07:05 am ET
Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Jul 26, 2018 04:05 pm ET
Intercept to Announce Second Quarter 2018 Financial Results on August 2, 2018 and Present at Upcoming Investor Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2018 financial results...
Jul 25, 2018 08:20 am ET
Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals — Future Exp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater Paper Corporation (NYSE:CLW), Intercept Pharmaceuticals, Inc....
Jun 07, 2018 05:00 pm ET
Intercept to Present at Upcoming Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
May 18, 2018 08:30 am ET
Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectatio
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG Mortgage Investment Trust, Inc. (NYSE:MITT), Associated Banc-Corp...
May 08, 2018 07:05 am ET
Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
May 01, 2018 05:00 pm ET
Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results...
Apr 24, 2018 08:00 am ET
Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its Board of Directors has appointed...
Apr 13, 2018 07:00 am ET
Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA)
Apr 05, 2018 08:30 am ET
Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its upsized...
Apr 04, 2018 04:05 pm ET
Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering and Concurrent $92 Million Private Placement of Common Stock
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten...
Mar 26, 2018 04:30 pm ET
Intercept to Present at Upcoming Conference
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in...
Mar 23, 2018 07:00 am ET
Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
Late-breaking presentation will feature the first clinical data from a biopsy-based substudy supporting obeticholic acid’s ability to reverse or stabilize fibrosis and cirrhosis in primary biliary cholangitis (PBC) patients
Mar 21, 2018 08:30 am ET
New Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Produ
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LTC Properties, Inc. (NYSE:LTC), NACCO Industries,...
Mar 13, 2018 05:48 pm ET
CORRECTING and REPLACING -- Intercept to Present at Upcoming Conference
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) please note that the conference date should be March 20, not March 19 as previously stated. The...
Feb 14, 2018 07:05 am ET
Feb 12, 2018 08:00 am ET
Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis
NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the REVERSE trial (Randomized Phase...
Feb 07, 2018 04:05 pm ET
Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth...
Jan 19, 2018 08:00 am ET
Detailed Research: Economic Perspectives on Basic Energy Services, Intercept Pharmaceuticals, Natus Medical, Surmodics, EnviroStarm, and Nicolet Bankshares — What Drives Growth in Today's Competitive
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Basic Energy Services, Inc. (NYSE:BAS), Intercept...
Dec 07, 2017 04:05 pm ET
Intercept to Present at Upcoming Conference
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the...
Nov 27, 2017 07:05 am ET
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Christian Weyer, M.D.,...
Nov 22, 2017 08:00 am ET
DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceu
STEVENSON, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District...
Nov 20, 2017 05:41 pm ET
The Klein Law Firm Reminds Shareholders of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- The Klein Law Firm reminders shareholders that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) who purchased shares between May 31, 2016...
Nov 16, 2017 04:59 pm ET
INTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Intercept Pharmaceuticals, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) of the November 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Nov 15, 2017 05:44 pm ET
ICPT EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017
NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf...
Nov 14, 2017 03:00 pm ET
Nov 11, 2017 07:01 pm ET
November 27, 2017 LEAD PLAINTIFF DEADLINE ALERT: Monteverde & Associates PC Encourages Investors Who Suffered Significant Losses in Intercept Pharmaceuticals, Inc. To Contact The Firm - ICPT
NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Notice is hereby given that a class action lawsuit has been filed, on behalf of shareholders of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NasdaqGS: ICPT) on behalf of  purchasers of the Company's securities between May 31, 2016 and September 20, 2017, inclusive (the "Class Period")....
Nov 11, 2017 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-07371, is on behalf of a class consisting of investors who purchased or otherwise acquired Intercept securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
Nov 08, 2017 06:23 pm ET
INTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) of the November 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Nov 08, 2017 06:23 pm ET
INTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) of the November 27, 2017 deadline to seek the...
Nov 07, 2017 12:48 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) from May 31, 2016...
Nov 01, 2017 05:30 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) securities between May 31, 2016 and September 20, 2017 (the “Class Period”). Investors have until November 27, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Nov 01, 2017 04:34 pm ET
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) who purchased shares between May 31, 2016 and September 20, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
Nov 01, 2017 03:34 pm ET
DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceutica
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept” or the “Company”) securities during the period between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 27, 2017 to seek appointment as lead
Nov 01, 2017 07:05 am ET
Oct 31, 2017 03:05 pm ET
ICPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ:ICPT) securities between May 31, 2016 and September 20, 2017.
Oct 31, 2017 03:04 pm ET
ICPT INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intercept Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Fir
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) securities between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”). Intercept investors have until 
Oct 29, 2017 06:30 pm ET
The Klein Law Firm Announces a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) who purchased shares between May 31, 2016 and September 20, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
Oct 28, 2017 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ICPT
NEW YORK, Oct. 28, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-07371, is on behalf of a class consisting of investors who purchased or otherwise acquired Intercept securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934....
Oct 26, 2017 01:00 am ET
ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 201
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ:ICPT) securities between May 31, 2016 and September 20, 2017.
Oct 25, 2017 05:00 pm ET
Intercept to Report Third Quarter 2017 Financial Results on November 1 and Present at Upcoming Conference
NEW YORK, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017 financial results prior to the NASDAQ market open on November 1, 2017. Intercept management will conduct a conference call and audio webcast on Wednesday, November 1, 2017 at 8:30 a.m. Eastern Time to discuss these results....
Oct 24, 2017 05:33 pm ET
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intercept Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm (ICPT)
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: 
Oct 23, 2017 04:02 pm ET
Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017
OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeksResults presented in a late-breaking oral session NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional results from the Phase 2 AESOP trial evaluating the investigational therapy obeticholic acid (OCA) for the treatment of patients with primary sclerosing cholangitis (PSC). These data were presented by le...
Oct 23, 2017 03:57 pm ET
ICPT LOSS NOTICE: Rosen Law Firm Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – ICPT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) securities from May 31, 2016 through September 20, 2017, both dates inclusive (the “Class Period”) of the important November 27, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.
Oct 23, 2017 10:10 am ET
Important Investor Alert: JFJN Law Announces Filing of a Class Action against Intercept Pharmaceuticals, Inc.
JFJN Law (the “firm) announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc., (“ICPT” or the “Company”) (Nasdaq:ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”) are encouraged to contact the Firm in advance of the November 27, 2017 lead plaintiff motion deadline.
Oct 20, 2017 04:30 pm ET
IMPORTANT INTERCEPT PHARMACEUTICALS, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Cou
NEW YORK, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ:ICPT) on behalf of investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the "Class Period")....
Oct 20, 2017 09:56 am ET
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.
The Klein Law Firm announces the commencement of an investigation of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) concerning possible violations of federal securities laws.
Oct 19, 2017 05:30 pm ET
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Reminds Investors with Losses Exceeding $100,000 to Contact the Fir
IRVINE, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq:ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the November 27, 2017 lead plaintiff motion deadline....
Oct 19, 2017 11:55 am ET
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.
The Klein Law Firm announces the commencement of an investigation of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) concerning possible violations of federal securities laws.
Oct 18, 2017 12:18 pm ET
ICPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intercept Pharmaceuticals, Inc. (“Intercept”) (NASDAQ:ICPT) violated federal securities laws.
Oct 17, 2017 10:14 am ET
ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, In
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intercept Pharmaceuticals, Inc. (“Intercept”) (NASDAQ:ICPT) violated federal securities laws.
Oct 16, 2017 01:29 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) concerning possible violations of federal securities laws.
Oct 13, 2017 10:00 am ET
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
CHAPEL HILL, N.C., Oct. 13, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Intercept (Nasdaq: ICPT) has extended its strategic partnership for TARGET-NASH to a multi-year agreement....
Oct 12, 2017 09:10 pm ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brow
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept” or the “Company”) securities during the period between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 27, 2017 to seek appointment as lead
Oct 12, 2017 05:40 pm ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:
Oct 10, 2017 02:00 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) from May 31, 2016 through September 20, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.
Oct 09, 2017 03:32 pm ET
EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
LOS ANGELES, Oct. 9, 2017 /PRNewswire/ -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq: ICPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Oct 09, 2017 01:38 pm ET
Robbins Arroyo LLP: Intercept Pharmaceuticals, Inc. (ICPT) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Intercept Pharmaceuticals, Inc. (NasdaqGS: ICPT). The complaint is brought on behalf of all purchasers of Intercept securities between May 31, 2016 and September 20, 2017, for all
Oct 04, 2017 06:29 pm ET
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq:ICPT) concerning possible violations of federal securities laws between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the November 27, 2017 lead plaintiff motion deadline....
Oct 04, 2017 06:08 pm ET
INTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Oct. 4, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ:ICPT) of the November 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Oct 04, 2017 03:21 pm ET
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., Oct. 4, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq: ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the November 27, 2017 lead plaintiff motion deadline. ...
Oct 03, 2017 02:48 pm ET
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, Oct. 3, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq: ICPT) concerning possible violations of federal securities laws between May 31, 2016 and September 20, 2017, inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the November 27, 2017 lead plaintiff motion deadline....
Sep 28, 2017 08:45 pm ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT)
STEVENSON, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (“Intercept” or the “Company”) securities during the period between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until November 27, 2017 to seek appointment as lead ...
Sep 27, 2017 04:19 pm ET
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017
NEW YORK, Sept. 27, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) securities and certain of its officers, on behalf of a class who purchased Acacia shares between May 31, 2016, and September 20, 2017, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/icpt.  ...
Sep 25, 2017 07:05 am ET
Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients
NEW YORK, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today provided comment on the Ocaliva (obeticholic acid or OCA) Dear Healthcare Provider (DHCP) letter issued on September 12, 2017, and the subsequent drug safety communication issued by the U.S. Food and Drug Administration (FDA) on September 21, 2017....
Sep 12, 2017 02:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK, Sept. 12, 2017 /PRNewswire-USNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc.("Intercept" or the "Company") (NASDAQ: ICPT).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Sep 01, 2017 04:05 pm ET
Intercept to Present at Upcoming Conferences
NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:...
Aug 01, 2017 10:31 am ET
Investors: covered-call reports for Advanced Micro Devices, Darden Restaurants, Intercept Pharmaceuticals, Micron and Zillow
CHICAGO, Aug. 1, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, DRI, ICPT, MU, and Z....
May 25, 2017 04:05 pm ET
Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC), when used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. ...
May 17, 2017 05:00 pm ET
Intercept to Present at Upcoming Conferences
NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:...
Apr 27, 2017 05:00 pm ET
Intercept to Report First Quarter 2017 Financial Results on May 4 and Present at Upcoming Conference
NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017 financial results prior to the NASDAQ market open on Thursday, May 4, 2017. Intercept management will conduct a conference call and audio webcast on Thursday, May 4, 2017 at 8:30 a.m. Eastern Time to discuss these results....
Mar 30, 2017 04:05 pm ET
Intercept to Present at Upcoming Conference
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:...
Mar 16, 2017 04:05 pm ET
Intercept to Present at Upcoming Conference
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:...
Feb 23, 2017 07:05 am ET
Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
Net Ocaliva® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 net sales of $18.2 millionEnrollment of Phase 3 REGENERATE interim analysis cohort anticipated completion by mid-2017Data expected from two Phase 2 trials for OCA in 2017Planned initiation of Phase 2 trial of INT-767 in 2017 Conference call scheduled for 8:30 a.m. ET today...
Jan 04, 2017 04:05 pm ET
Intercept to Present at Upcoming Investor Conference
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:...
Dec 09, 2016 05:00 pm ET
Intercept to Present at Upcoming Investor Conference
NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following investor conference:...
Dec 06, 2016 09:31 am ET
Amazon.com trade offers a 6.05% return in 74 days, or find similar option trades on Intercept Pharmaceuticals, Energous Corporation, Opko Health, and 3D Systems
CHICAGO, Dec. 6, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, DDD, ICPT, OPK, and WATT....
Nov 01, 2016 07:05 am ET
Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting
NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced multiple Ocaliva® (obeticholic acid) for PBC and INT-767 data presentations at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), taking place November 11 – 15 in Boston, MA. ...
Oct 28, 2016 04:05 pm ET
Intercept to Report Third Quarter 2016 Financial Results on November 3
NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its third quarter 2016 financial results prior to the NASDAQ market open on Thursday, November 3, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, November 3, 2016 at 8:30 a.m. Eastern Time to discuss these results....
Oct 14, 2016 07:35 am ET
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
NEW YORK, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization of the Company’s Marketing Authorization Application (MAA) for obeticholic acid (OCA), an FXR agonist, for the treatment of primary biliary cholangitis (PBC) conditional...
Sep 02, 2016 07:30 am ET
Intercept to Present at Upcoming Investor Conferences
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:...
Aug 04, 2016 07:05 am ET
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Ocaliva® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenueREGENERATE NASH trial targeted to complete enrollment for interim analysis in 1H17 Conference call scheduled for 8:30 am ET today             ...
Jul 28, 2016 07:05 am ET
Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
NEW YORK, July 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results....
Jul 06, 2016 05:05 pm ET
Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes
NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to purchase an additional $60 million in aggregate principal amount of notes to cover over-allotments. As a result, Intercept anticipates that the aggregate net proceeds, after deducting the underwriting discount and estimated offering expenses payable by Int...
Jun 30, 2016 09:17 am ET
Intercept Pharmaceuticals Announces Pricing of Public Offering of Convertible Senior Notes
NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes). Intercept has granted the underwriters an option, exercisable for 30 days, to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments. The offering is expected to close on or about July 6, 2016, subject to customary closing conditions....
Jun 29, 2016 04:15 pm ET
Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes
NEW YORK, June 29, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today that it has commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 (the notes). RBC Capital Markets, UBS Investment Bank, BofA Merrill Lynch, Citigroup and Credit Suisse are acting as joint book-running managers for the offering. Intercept intends to grant the underwriters an option, exercisable for 30 days, to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions,...
Jun 09, 2016 05:35 pm ET
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced  the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009.  Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership....
Jun 01, 2016 04:05 pm ET
Intercept to Present at Upcoming Investor Conferences
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:...
May 27, 2016 11:42 pm ET
May 24, 2016 07:30 am ET
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee....
May 18, 2016 11:00 am ET
Intercept Announces Ocaliva™ (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week® (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or...
Apr 28, 2016 04:45 pm ET
Intercept to Report First Quarter 2016 Financial Results on May 5
NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ Market closes on Thursday, May 5, 2016. Intercept management will conduct a conference call and webcast on Thursday, May 5, 2016 at 5:00 p.m. ET to discuss these results....